## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Applicants

MEIJER, Christophorus et al.

U.S. Serial No.

10/551,584

U.S. Filed on

September 29, 2005

In connection with

Int'l. App. No.

PCT/NL2004/000118

Int. Filing Date

February 17, 2004

For :

DETECTION FOR HPV-INDUCED INVASIVE CANCERS

AND THEIR PRECURSOR LESIONS WITH INVASIVE

POTENTIAL

COOPER & DUNHAM LLP 1185 Avenue of the Americas New York, NY 10036 November 3, 2005

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **INFORMATION DISCLOSURE STATEMENT**

Pursuant to applicants' duty of disclosure, applicants wish to call to the attention of the Examiner in charge of the above-identified application the references listed on the enclosed forms PTO/SB/08A and PTO/SB/08B, copies of which are provided herewith. The Examiner is respectfully requested to review the reference and make them of record in the application.

Applicants: MEIJER, Christophorus et al.

U.S. Serial No.: 10/551,584

Based on Int'l. Serial No.: PCT/NL2004/000118

Page 2

The Commissioner is hereby authorized to charge any additional fee required in connection with the filing of this Information Disclosure Statement to Deposit Account 03-3125.

Respectfully submitted,

Dated: Nov. 3, 2005

Robert D. Katz - Reg. No. 30,141

Attorney for Applicants COOPER & DUNHAM LLP 1185 Avenue of the Americas New York, New York 10036

(212) 278-0400

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Complete if Known				
Application Number	10/551,584			
Filing Date	September 29, 2005			
First Named Inventor	Christophorus MEIJER			
Art Unit				
Examiner Name				
Attorney Docket Number	2700/75210 DCT_US/PDK			

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number-Kind Code <sup>2 (# known)</sup>	Number-Kind Code <sup>2</sup> (* Mown)			Figures Appear
		US-			
		UŚ-			
		US-		······································	
	<b></b> -	US-			
		ŲS-		·	
•		US-		-	
		US-			
		US-			
		US-	-		
		US-			
-		US-			

		FOREIG	GN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	П
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		WO 99/29890	06-17-1999	LORINCZ		
		WO 02/14557	02-21-2002	REEVES et al.		
	ļ					-
	ļ					<u> </u>
	[				İ	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at \(\frac{\text{ww.uspto.gov}}{\text{uspto.gov}}\) or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\)Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known					
3-3-3-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1				Application Number	10/551,584		
			CLOSURE	Filing Date	September 29, 2005		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Christophorus MEIJER		
	(Use as many she	ate se r	eressend	Art Unit			
lose as many sheets as necessary,				Examiner Name			
Sheet	2	of	2	Attorney Docket Number	2799/75219-PCT-US/RDK		

		NON PATENT LITERATURE DOCUMENTS	<u> </u>
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		FUKUHARA, H. et al., "Promoter Methylation of TSLC1 and Tumor Suppression by Its Gene Product in Human Prostate Cancer," Jpn. J. Cancer Res., 2002, 605-609, vol. 93	
	:	STEENBERGEN, R. et al., "TSLC1 Gene Silencing in Cervical Cancer Cell Lines and Cervical Neoplasia," Journal of the National Cancer Institute, 2004, 294-305, vol. 96, no. 4	
		PULIDO, H. et al., "Identification of a 6-cM Minimal Deletion at 11q23.1-23.2 and Exclusion of PPP2R1B Gene," Cancer Research, 2000, 6677-6682, vol. 60	
		LIST, H-J. et al., "Methylation Sensitivity of the Enhancer from the Human," The Journal of Biological Chemistry, 1994, 11902-11911, vol. 269, no. 16	

	 		_
Examiner		Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: